Efficacy and safety of Eribulin-based chemotherapy in HER2 negative advanced breast cancer patients: a real-world study
BackgroundBreast cancer is recognized as one of the most common cancers worldwide, exhibiting a notably high incidence rate among women in China. Despite significant advancements in therapeutic approaches, the prognosis for patients diagnosed with advanced stages of the disease remains poor. Therefo...
Saved in:
| Main Authors: | Yuting Li, Dan Han, Ting Hu, Jie Xiong, Yuehua Wang, Yanxia Zhao |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1499701/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
10 years of success achieved by eribulin while treating HER2-negative mBC: from randomized studies to routine practice
by: I. V. Kolyadina
Published: (2021-10-01) -
Efficacy and safety of eribulin mesylate in advanced soft tissue sarcomas
by: Jonathan Noujaim, et al.
Published: (2016-01-01) -
Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
by: Herleeyana Meriyani, et al.
Published: (2025-02-01) -
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01) -
CLINICAL ECONOMIC ANALYSIS OF USING ERIBULIN (HALAVEN®) FOR TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER
by: S. L. Plavinsky, et al.
Published: (2016-02-01)